Sugi Predict

Sugi Predict / Compounds / SCHEMBL4479596

SCHEMBL4479596

SCHEMBL4479596

CCC[C@H](C(N)=O)[C@@H](CC1CCCC1)C(=O)NC1N=C(c2ccccc2)c2ccccc2N(Cc2cccc(Oc3ccccc3)c2)C1=O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NOTCH1 P46531 11/20 0.55
▸ RBPJ Q06330 3/20 0.55
▸ PSEN1 P49768 2/20 0.55
▸ PSEN2 P49810 2/20 0.55
▸ APH1B Q8WW43 2/20 0.55
▸ NCSTN Q92542 2/20 0.55
▸ APH1A Q96BI3 2/20 0.55
▸ PSENEN Q9NZ42 2/20 0.55
▸ NOTCH3 Q9UM47 8/20 0.53
▸ OXTR P30559 1/20 0.53
▸ CCKAR P32238 1/20 0.46
▸ APP P05067 3/20 0.45
▸ MMP1 P03956 1/20 0.45
▸ MMP2 P08253 1/20 0.45
▸ MMP7 P09237 1/20 0.45
▸ MMP10 P09238 1/20 0.45
▸ MMP9 P14780 1/20 0.45
▸ MMP13 P45452 1/20 0.45
▸ MMP14 P50281 1/20 0.45
▸ ADAM17 P78536 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4498666 0.99 NOTCH1 (0.55) NOTCH1RBPJPSEN1PSEN2APH1B
SCHEMBL4500924 0.97 NOTCH1 (0.56) NOTCH1RBPJPSEN1PSEN2APH1B
SCHEMBL4491135 0.96 OXTR (0.53) NOTCH1RBPJPSEN1PSEN2APH1B
SCHEMBL4485495 0.95 OXTR (0.52) NOTCH1RBPJPSEN1PSEN2APH1B
SCHEMBL4492425 0.93 NOTCH1 (0.51) NOTCH1RBPJPSEN1PSEN2APH1B
SCHEMBL4487685 0.90 NOTCH1 (0.53) NOTCH1RBPJPSEN1PSEN2APH1B
SCHEMBL4488057 0.90 NOTCH1 (0.57) NOTCH1RBPJPSEN1PSEN2APH1B
SCHEMBL4486538 0.90 NOTCH1 (0.54) NOTCH1RBPJPSEN1PSEN2APH1B
SCHEMBL4488323 0.90 NOTCH1 (0.69) NOTCH1RBPJPSEN1PSEN2APH1B
SCHEMBL6090789 0.89 NOTCH1 (0.55) NOTCH1RBPJPSEN1PSEN2APH1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080293692-A1 SUCCINOYLAMINO LACTAMS AS INHIBITORS OF A-BETA PROTEIN PRODUCTION BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2008-11-27 — — US claimed
US-6962913-B2 Benzo-1,4-diazepin-2-ones as inhibitors of Aβ protein production BRISTOL-MYERS SQUIBB COMPANY (US) 2005-11-08 — — US claimed
US-20050245501-A1 Succinoylamino lactams as inhibitors of A-beta protein production BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2005-11-03 — — US claimed
US-20030134841-A1 Succinoylamino lactams as inhibitors of A-beta protein production OLSON RICHARD E (US) 2003-07-17 — — US claimed
US-7507815-B2 Succinoylamino lactams as inhibitors of a-β protein production BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2009-03-24 — — US disclosed
US-20080293692-A1 SUCCINOYLAMINO LACTAMS AS INHIBITORS OF A-BETA PROTEIN PRODUCTION BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2008-11-27 — — US disclosed
US-7304056-B2 Succinoylamino lactams as inhibitors of Aβ protein production BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2007-12-04 — — US disclosed
US-7304055-B2 Succinoylamino lactams as inhibitors of Aβ protein production BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2007-12-04 — — US disclosed
US-20060264417-A1 Succinoylamino lactams as inhibitors of a-beta protein production BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2006-11-23 — — US disclosed
US-20060258638-A1 Succinoylamino lactams as inhibitors of A-beta protein production BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2006-11-16 — — US disclosed
US-7101870-B2 Succinoylamino lactams as inhibitors of A-β protein production BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2006-09-05 — — US disclosed
US-6962913-B2 Benzo-1,4-diazepin-2-ones as inhibitors of Aβ protein production BRISTOL-MYERS SQUIBB COMPANY (US) 2005-11-08 — — US disclosed
US-20050245501-A1 Succinoylamino lactams as inhibitors of A-beta protein production BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2005-11-03 — — US disclosed
US-6794381-B1 BETA -PEPTIDE INHIBITOR PREVENTS NEUROLOGICAL DEPOSITS OF AMYLOID PRECURSOR PROTEIN; ALZHEIMER'S DISEASE AND DOWN'S SYNDROME TREATMENT BRISTOL-MYERS SQUIBB COMPANY 2004-09-21 — — US disclosed
US-20030134841-A1 Succinoylamino lactams as inhibitors of A-beta protein production OLSON RICHARD E (US) 2003-07-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060264417-A1 Succinoylamino lactams as inhibitors of a-beta protein production BACE1, APH1A, APP NOTCH1 94/4885RBPJ 1902/4885PSEN1 7/4885
US-20080293692-A1 SUCCINOYLAMINO LACTAMS AS INHIBITORS OF A-BETA PROTEIN PRODUCTION BACE1, APH1A, APP NOTCH1 94/4885RBPJ 1902/4885PSEN1 7/4885
US-20050245501-A1 Succinoylamino lactams as inhibitors of A-beta protein production BACE1, APH1A, APP NOTCH1 94/4885RBPJ 1902/4885PSEN1 7/4885
US-20060258638-A1 Succinoylamino lactams as inhibitors of A-beta protein production BACE1, APH1A, APP NOTCH1 94/4885RBPJ 1902/4885PSEN1 7/4885
US-20030134841-A1 Succinoylamino lactams as inhibitors of A-beta protein production APH1A, BACE1, APP NOTCH1 125/4885RBPJ 1850/4885PSEN1 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.